NO912864L - Stedsspesifikk in vivo-aktivering av terapeutiske forbindelser - Google Patents

Stedsspesifikk in vivo-aktivering av terapeutiske forbindelser

Info

Publication number
NO912864L
NO912864L NO91912864A NO912864A NO912864L NO 912864 L NO912864 L NO 912864L NO 91912864 A NO91912864 A NO 91912864A NO 912864 A NO912864 A NO 912864A NO 912864 L NO912864 L NO 912864L
Authority
NO
Norway
Prior art keywords
activator
prodrug
target tissue
targeting moiety
vivo activation
Prior art date
Application number
NO91912864A
Other languages
English (en)
Other versions
NO912864D0 (no
Inventor
Reinhard Bredehorst
Chong-Ho Kim
Richard Mccabe
Nicholas Pomato
Carl-Wilhelm Vogel
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23161497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO912864(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of NO912864D0 publication Critical patent/NO912864D0/no
Publication of NO912864L publication Critical patent/NO912864L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1. Aktivator-målsøkingsdel-konjugat, karakterisert ved at det omfatter lysozym som aktivator og et humant monoklonalt antistoff eller et fragment av dette som målsøkingsdel. 2. Prodroge, karakterisert ved at den omfatter et anti- kreftmiddel som bærer et spaltbart molekyl som hindrer celle- opptak. 3. Prodroge ifølge krav 2, karakterisert ved at den omfatter et anti- kreftmiddel som er derivatisert med et kitinoligomer-avstands- materiale. 4. Prodroge ifølge krav 3, karakterisert ved at antikreftmidlet er et antracyklin. 5. Prodroge ifølge krav 4, karakterisert ved at kitinoligomer-avstands- materialet er festet via en aminogruppe på et sted valgt fra gruppen som består av C13-karbonylstedet på antracyklinet og sukkerdelen av antracyklinet. 6. Prodroge ifølge krav 5, karakterisert ved at kitinoligomer-derivatet inneholder (GlcNAc)n, hvor n er 1-10, som bærer negativt ladede grupper og en reaktiv gruppe som gir mulighet for kovalent festing til antracyklinet. 7. Prodroge ifølge krav 6, karakterisert ved at de negativt ladede grupper representerer sulfonater, fosfater, karboksylater eller fosfonater. 8. Prodroge ifølge krav 6, karakterisert ved at antallet negativt ladede grupper er fra l til 10. 9. Prodroge ifølge krav 3, karakterisert ved at kitinoligoroer-avstands- materialet er bundet kovalent til drogen via en aktiv gruppe valgt blant disulfid-, tioester-, imid-, halogen-, amin-, karboksyl-, ester-, tiol- og alkoholgrupper. 10. Prodroge ifølge krav 6, karakterisert ved at den reaktive gruppe er valgt blant disulfid-, tioester-, imid-, halogen-, amin-, karboksyl-, ester-, tiol- og alkoholgrupper.
NO91912864A 1989-01-23 1991-07-22 Stedsspesifikk in vivo-aktivering av terapeutiske forbindelser NO912864L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30099989A 1989-01-23 1989-01-23
PCT/US1990/000503 WO1990007929A1 (en) 1989-01-23 1990-01-23 Site specific in-vivo activation of therapeutic drugs

Publications (2)

Publication Number Publication Date
NO912864D0 NO912864D0 (no) 1991-07-22
NO912864L true NO912864L (no) 1991-09-19

Family

ID=23161497

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91912864A NO912864L (no) 1989-01-23 1991-07-22 Stedsspesifikk in vivo-aktivering av terapeutiske forbindelser

Country Status (12)

Country Link
EP (1) EP0454783B1 (no)
JP (1) JP3273608B2 (no)
KR (1) KR0185967B1 (no)
AT (1) ATE123414T1 (no)
AU (1) AU648015B2 (no)
CA (1) CA2025899A1 (no)
DE (1) DE69019959T2 (no)
DK (1) DK0454783T3 (no)
ES (1) ES2075893T3 (no)
FI (1) FI97692C (no)
NO (1) NO912864L (no)
WO (1) WO1990007929A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
ATE233100T1 (de) * 1989-08-02 2003-03-15 Mitra Medical Technology Ab System zur verwendung in einem verfahren zur therapeutischen und diagnostischen behandlung
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
ATE177321T1 (de) * 1989-12-11 1999-03-15 Immunomedics Inc Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper
SE9100142L (sv) 1991-01-17 1992-07-18 Bengt Sandberg En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
AU4663493A (en) * 1992-07-06 1994-01-31 Hybritech Incorporated Method for delivery of cytotoxic agents and components thereof
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
BR9510490B1 (pt) * 1994-12-23 2010-10-05 composição farmacêutica combinada de dois componentes estruturada para uso em um hospedeiro.
BR9610050A (pt) 1995-08-16 1999-10-13 Zeneca Ltd Conjugado,sitemas de dois componentes combinados destinados a uso em um hospedeiro, compostos ou um sal destes famaceuticamente aceitavel,enzima,sequencia de polinucleotìdeos e de02 nucleotìdeos,vetor, célula hospedeira,processos de producão de uma enzima e de um conjugado e de tratamento de célulasneoplásticas em um hospedeiro,composicão farmaceutica e plasmìdeo
ATE316799T1 (de) * 1996-03-12 2006-02-15 Sanofi Aventis Deutschland Neuartige prodrugs für die therapie von tumoren und entzündlichen erkrankungen
PL229108B1 (pl) * 2014-08-22 2018-06-29 Celther Polska Spolka Z Ograniczona Odpowiedzialnoscia Sposób wydzielania i oczyszczania estrów chityny (mono-, di‑podstawionych) oraz kopoliestrów chityny z mieszanin poreakcyjnych

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067774A (en) * 1971-05-14 1978-01-10 Syva Company Compounds for enzyme amplification assay
LU85581A1 (fr) * 1984-10-10 1986-06-11 Smb Lab Ensembles d'anticorps monoclonaux diriges contre la lactoferrine humaine et le lysozyme humain
JPS62138496A (ja) * 1985-12-11 1987-06-22 Ihara Chem Ind Co Ltd キチンオリゴマ−の製造方法
ATE137674T1 (de) * 1987-07-02 1996-05-15 Akzo Nobel Nv Von mca 16-88 erkanntes antigen
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies

Also Published As

Publication number Publication date
FI97692B (fi) 1996-10-31
DE69019959T2 (de) 1995-10-05
AU648015B2 (en) 1994-04-14
JP3273608B2 (ja) 2002-04-08
DK0454783T3 (da) 1995-10-16
AU5039790A (en) 1990-08-13
EP0454783B1 (en) 1995-06-07
KR0185967B1 (ko) 1999-05-01
JPH04503068A (ja) 1992-06-04
EP0454783A1 (en) 1991-11-06
WO1990007929A1 (en) 1990-07-26
CA2025899A1 (en) 1990-07-24
NO912864D0 (no) 1991-07-22
KR910700072A (ko) 1991-03-13
ATE123414T1 (de) 1995-06-15
FI97692C (fi) 1997-02-10
DE69019959D1 (de) 1995-07-13
FI913511A0 (fi) 1991-07-22
ES2075893T3 (es) 1995-10-16
EP0454783A4 (en) 1992-01-15

Similar Documents

Publication Publication Date Title
NO912864L (no) Stedsspesifikk in vivo-aktivering av terapeutiske forbindelser
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
DE3277453D1 (en) Use of eucalyptol for enhancing skin permeation of bioaffecting agents
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
GB9710049D0 (en) Method
DE69215722D1 (de) Verstärker zur Ultraschalltherapie von Erkrankungen sowie diesen enthaltende flüssige Arzneimittelzusammensetzungen
DE69116380T2 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DK164441C (da) Anvendelse af et piperidinderivat til fremstilling af et farmaceutisk praeparat til behandling af smertetilstande
MXPA02012075A (es) Composicion para mediar el dolor y aparato y metodo para utilizarla.
IL146133A0 (en) Preparations for the application of anti-inflammatory agents
DE69835461D1 (de) Anti-arrhythmische Zusammensetzungen und Behandlungsverfahren
Newell Pharmacokinetically guided dose escalation in phase I clinical trials: Commentary and proposed guidelines.
GR3032224T3 (en) Therapeutic agent for threatened abortion.
AU5643299A (en) Humic acid and its use in the treatment of various conditions
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
WO2001007029A3 (en) Substituted guanidines and the use thereof
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
Bredehorst et al. Site specific in vivo activation of therapeutic drugs
DK452788D0 (da) Smertestillende praeparat
KR890007737A (ko) 진토작용을 하는 약제
KR890001555A (ko) 요산 배설용 조성물
MX9302929A (es) Derivados de tetrahidro y perhidroisoquinolina y medios terapeuticos que los contienen.
CA2186752A1 (en) Drug treatment of diseased sites deep within the body
UA23921A (uk) Спосіб лікування шлунково-стравохідного рефлюксу